KYLYS AESTHETICS SA Completes its First Clinical Trial

KYLYS AESTHETICS SA, a University of Geneva spinoff and Swiss clinical-stage biotech company developing next-generation regenerative aesthetic medical devices, announces the successful completion of patient injections in its first clinical trial.

A total of 55 patients have now been treated as part of this study evaluating the company’s proprietary hyaluronic acid-based injectable technology. This milestone marks a significant step forward in the clinical development of KYLYS AESTHETICS’ Class III medical device. The trial is designed to assess safety, performance, and clinical behavior of the product. All planned patient injections have
been completed in accordance with the approved clinical protocol.

Preliminary observations following the injections are promising, showing outcomes consistent with the company’s expectations in terms of product handling, tissue integration, and aesthetic performance. Full clinical data analysis is currently ongoing and will be completed in line with regulatory and clinical best practices.

KYLYS AESTHETICS’ technology is based on a patented hyaluronic acid platform. The company’s approach aims to go beyond traditional volumizing fillers by focusing on regenerative properties, natural integration into targeted tissues, and clinical performance.

➡️ Source: Press release | 📸 KYLYS AESTHETICS’ founding team, ©KYLYS AESTHETICS